Ottobock has successfully enhanced its market leadership and financial performance in 2024 with a strategic acquisition and continuous innovation in its healthtech solutions.
Information on the Target
Ottobock is a global health technology company recognized as one of the leading providers of customized prosthetic and orthotic mobility solutions. In 2024, the company reported a 7% increase in revenue compared to the previous year, reaching over €1.6 billion, up from €1.495 billion in 2023. Additionally, Ottobock's adjusted EBITDA rose by 17%, exceeding €325 million in 2024, up from €280 million the previous year.
CEO Oliver Jakobi noted, "Our performance in 2024 demonstrates that our strong focus on innovation pays off. We are effectively translating our technological advances into commercial success, fostering sustainable growth, setting new standards, and entering new markets. As we enter 2025, we are optimistic about continuing on this upward trajectory, supported by newly established reimbursements in key markets."
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target's Specific Country
In recent years, the healthcare technology industry in Germany has witnessed significant growth, driven by advancements in medical technology and an increasing demand for pe
Similar Deals
Philip Morris International → Fertin Pharma
2023
Ottobock
invested in
Sahva A/S
in 2024
in a Other deal
Disclosed details
Revenue: $1,715M
EBITDA: $355M